Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in the Bloomberg BNA Health Care Daily Report, in “Cures Act Adds Tough Penalties for Electronic Information Blocking,” by James Swann. (Read the full version – subscription required.)
Following is an excerpt:
Bradley Merrill Thompson, a health-care attorney with Epstein Becker & Green PC in Washington, told Bloomberg BNA Dec. 14 that Cures provides some much-needed regulatory clarity as to what will be regulated.
“For example, the legislation incorporates the common sense notion that if a physician has access to all of the underlying information such that the physician can double-check the basis for any recommendation, then the software is really simply supporting the physician in his or her practice,” and such software shouldn't be regulated by the FDA, and the new law reinforces that point, Thompson said.
